Patients with Brain Metastases | Afatinib NSCLC Trials | InOncology
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials - Lung Cancer
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives | Oncotarget
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials - The Lancet Oncology
Survival Outcomes by Age Subgroup in LUX-Lung 3 and LUX-Lung 6 | Download Table
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials - The Lancet Oncology
mNSCLC with EGFR del19 Mutation | GILOTRIF® (afatinib)
LUX-Lung 8 A randomised, open-label phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line. - ppt download
Afatinib versus gemcitabine/cisplatin for first-line treatment of Chin | OTT
Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations - Clinical Lung Cancer
LUX-Lung 3 & 6 Clinical Trial results Infographic | boehringer-ingelheim.com.br
Moving Care Forward in Advanced NSCLC: Optimizing Multidisciplinary Management (Transcript)
InOncology | LUX-Lung 3 Clinical Trial | Afatinib NSCLC Trials & Studies | Boehringer Ingelheim
PFS in recent head-to-head trials: (a) Lux-Lung 7, (b) ARCHER 1050 and... | Download Scientific Diagram
Patients with Brain Metastases | Afatinib NSCLC Trials | InOncology
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX- Lung 7 trial - Annals of Oncology
GIOTRIF®（afatinib）Efficacy | BI
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer - Journal of Thoracic
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial - Annals of Oncology
mNSCLC with EGFR del19 Mutation | GILOTRIF® (afatinib)
Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients - ESMO Open
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials - The Lancet Oncology
LUX Lung 3 Clinical Trial Infographic (Boehringer Ingelheim) | Clinical trials, Boehringer ingelheim, Trials
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases - Journal of Thoracic Oncology
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 | British Journal of Cancer
EGFR-mutation-positive NSCLC: expanding the data pool for established treatment options - memoinOncology
